The Scottish Medicines Consortium (SMC) has published a position statement explaining how pharmaceutical companies should disclose and govern the use of artificial intelligence in medicines submissions. Announced on 3 November 2026, the document provides concrete expectations for AI-assisted evidence generation, prompt transparency, validation, model traceability and human oversight.
Saturday, November 7, 2026
Scottish Medicines Consortium (SMC) has published a new framework for responsible AI use in medicines submissions
Wednesday, November 4, 2026
LLM-Assisted SOP Generation Enters a GLP/GMP-Aligned LIMS-QMS Pilot
A peer-reviewed paper published on 20 October 2026 describes the pilot deployment of a laboratory informatics platform combining LIMS and QMS functions with a Large Language Model module capable of generating draft SOPs, required-material lists, risk assessments and executable laboratory workflows. The study is important not because it proves that LLM-generated SOPs are ready for unsupervised GMP use, but because it documents a governance-first architecture and clearly identifies the controls and evidence that remain incomplete.
EMA Moves AI in Pharmacovigilance from Experimentation to Operational Deployment
The European Medicines Agency has published a detailed update showing that artificial intelligence is moving from experimental pharmacovigilance projects into operational regulatory workflows. The presentation, published on 30 October 2026, describes deployed AI tools, measurable pilot results, a network-wide framework for sharing AI tools and a five-year European project on AI-powered signal detection.